Clinical trial
SB-773812 Administered In Adults With Schizophrenia
NCT00259870 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00259870 |
|---|---|
| Title | SB-773812 Administered In Adults With Schizophrenia |
| Official title | A Multi Centre, Double-Blind, Double-Dummy, Placebo-Controlled, Randomised, Adaptive, Dose-Range Study To Evaluate the Safety and Efficacy of SB-773812 Administered Once Daily for 12 Weeks in Adults With Schizophrenia |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | SB-773812, Olanzapine |
| Enrollment | 338 |
| Start date | Sep 1, 2005 |
| Completion | Aug 1, 2007 |
| First posted | Dec 1, 2005 |
| Last update posted | Mar 23, 2017 |
| Countries | Belgium, Costa Rica, Czechia, India, Peru, Russia, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: